Global Non-Hematological Cancers Market to Hit $140.8 Billion by 2021, says GBI Research

LONDON, April 8, 2016 /PRNewswire/ --

A new report from business intelligence provider GBI Research - Global Non-Hematological Cancers Market to 2021 - states that the global treatment market for non-hematological cancers, which includes breast, colorectal, lung and prostate cancers, among others, will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, at a compound annual growth rate (CAGR) of 9.9%.

This robust growth will occur in spite of the patent expiries of a number of very commercially successful products, including Avastin, Erbitux and Herceptin. Avastin will see its first expiry in the EU in 2018, with the two others having already experienced EU expiries in 2014.

Associate Analyst Adam Bradbury explains: "These drugs are all monoclonal Antibodies (mAbs), and are therefore expected to be less susceptible to market share and price erosion following patent expiry, due to practical and regulatory barriers to entry for biosimilars. In this way, these expirations will not pose too strong a barrier to growth."

Market drivers will include the increasing prevalence of cancer globally, and the introduction of more targeted treatments, which will improve the overall survival of poor-performance-status patients and enable more rounds of chemotherapy to be administered.

GBI Research also states that in terms of the pharmaceutical pipeline for non-hematological cancers, there are 2,954 products in active development, 171 of which are in Phase III development or Pre-registration.

Bradbury explains: "Although none of the products in the late-stage pipeline are expected to reach the same levels of success as the highest revenue-generating drugs currently in the market, due to the competitiveness of the landscape, there are a number of candidates that are expected to achieve strong sales during the forecast period. These include AZD-4736 and neratinib, which are both forecast to generate blockbuster revenues by 2021.

"A range of companies are actively involved in the development or marketing of these new oncology products, including most of the top 20 pharmaceutical companies, smaller publicly traded companies and privately-held enterprises. In particular, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, and Novartis, are anticipated to maintain their strong market shares throughout the forecast period.

"While Roche's market share within non-blood cancers is anticipated to decrease, partly due to the approaching patent expiries of Avastin and Tarceva, Roche is still expected to maintain the highest market share for non-hematological cancer treatment of any company throughout the forecast period."

Sample pages of GBI Research's report Global Non-Hematological Cancers Market to 2021 are available upon request

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. For more information about our offerings, please contact us on:

+44-(0)161-359-5817 

Connect with GBI Research on social media for the latest healthcare market updates:

Facebook | LinkedIn | Twitter

SOURCE GBI Research